Özlem TEKİN, Fatih TEKİN, Ömer Faruk TANER, Ergin IŞIK, Mehmet SÜRMELİ, Zeynep ÇİZMECİ, Derun Taner ERTUĞRUL

Is there any difference in tetanus IgG levels of diabetic patients with respect to the presence of foot ulcers?

Background/aim: The aim of this study was to reveal the tetanus immunization status of diabetic patients and to determine whether diabetic patients with foot ulcers have different TIG levels. Materials and methods: A cross-sectional study was designed that included diabetic patients with foot ulcers (n = 30) and diabetic patients without ulcers (n = 30). The groups were compared for serum TIG levels along with total serum protein, albumin, C-reactive protein (CRP), and total immunoglobulin G (Ig G). Results: For diabetic patients without foot ulcers, 17 of 30 (56.6%) patients were found to have nonprotective TIG levels whereas for diabetic patients with foot ulcers, 28 of 30 (93.3%) patients were found to have nonprotective TIG levels. The mean value of TIG for diabetic patients without foot ulcers was 0.345 ± 0.281 IU/mL and for diabetic patients with foot ulcers the mean TIG value was 0.055 ± 0.033 IU/mL. Statistically significant differences were observed in TIG (P = 0.008), total protein (P < 0.001), albumin (P < 0.001), and CRP levels (P < 0.001) between the two groups. Conclusion: The majority of the diabetic patients had low TIG levels and they were significantly lower in diabetic patients with ulcers. A booster dose of tetanus vaccine should be considered for diabetic patients with and without diabetic foot ulcers.

PDF

___

1. Hamborsky JKA, Wolfe S. Epidemiology and Prevention of Vaccine-Preventable Diseases 13th ed. Washington DC, USA: Public Health Foundation; 2015. pp. 341-342.
2. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992; 267: 21338-21343.
3. Rossetto O, Scorzeto M, Megighian A, Montecucco C. Tetanus neurotoxin. Toxicon 2013; 66: 59-63.
4. Centers for Disease Control and Prevention. Tetanus Surveillance - United States, 2001-2008. MMWR 2011; 30: 365-395.
5. World Health Organization. The World Health Report 1998: life in the 21st century - A vision for all. 1998: pp. 39-60.
6. Körber A, Graue N, Rietkötter J, Kreuzfelder E, Grabbe S, Dissemond J. Insufficient Tetanus Vaccination Status in Patients with Chronic Leg Ulcers. Dermatology 2008; 217: 69- 73.
7. Nemati M, Zarrin M, Mir-Abdollah SA, Rezayati MT, Mirzaee V, Bagheri A, Ebrahimi M, Jafarzadeh A. Lower serum level of anti-tetanus toxin antibodies in patients with type 2 diabetes mellitus. Acta Med Indones 2014; 46: 44-50.
8. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillanceUnited States, 19982000. MMWR Surveill Summ 2003; 52: 1-8.
9. Farnworth E, Roberts A, Rangaraj A, Minhas U, Holloway S, Harding K. Tetanus in patients with chronic wounds - are we aware? Int Wound J 2012; 9: 93-99.
10. Gardner AW, Afaq A. Management of lower extremity peripheral arterial disease. J Cardiopulm Rehabil Prev 2008; 28: 349-357.
11. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lowerextremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162.
12. Rogers LC, Frykberg RG. Tetanus prophylaxis for diabetic foot ulcers. Clin Podiatr Med Surg 2006; 23: 769-775.
13. Daoud AK, Tayyar MA, Fouda IM, Harfeil NA. Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions. J Immunotoxicol 2009; 6: 36-41.
14. Takeda Y, Marumo M, Wakabayashi I. Attenuated phagocytic activity of monocytes in type 2 diabetic Goto-Kakizaki rats. Immunobiology 2011; 216: 1094-1102.
15. Eibl N, Spatz M, Fischer GF, Mayr WR, Samstag A, Wolf HM, Schernthaner G, Eibl MM. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103: 249-259.
16. Jirkovska A, Fejfarova V, Hosova J, Striz I, Kalanin J, Skibova J. Analysis of the inflammation reaction and selected indicators of immunity in patients with an infected diabetic ulcer. Cas Lek Cesk 2002; 141: 483-486.
17. Alexiewicz JM, Kumar D, Smogorzewski M, Massry SG. Elevated cytosolic calcium and impaired proliferation of B lymphocytes in type II diabetes mellitus. Am J Kidney Dis 1997; 30: 98-104.
18. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26: 259-265.
19. Kilic D, Kaygusuz S, Saygun M, Cakmak A, Uzer H, Doganci L. Seroprevalence of tetanus immunity among noninsulindependent diabetes mellitus patients. J Diabetes Complications 2003; 17: 258-263.
20. Tamer A, Karabay O, Ekerbicer H, Tahtaci M, Selam B, Celebi H. Impaired immunity against tetanus in type 2 diabetes. Med Sci Monit 2005; 11: CR580-584.
21. Dodet B. Immunity in the elderly. Vaccine 2000; 18: 1565.
22. Murr C, Hainz U, Asch E, Berger P, Jenewein B, Saurwein-Teissl M, Grubeck-Loebenstein B, Fuchs D. Association of increased neopterin production with decreased humoral immunity in the elderly. Exp Gerontol 2003; 38: 583-587.
23. Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth 2001; 87: 477-487.
24. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine 2010; 28: 3773-3777.
25. Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, Cho S, Seong BL, Ahn CW, Lee JM. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea. Diabet Med 2011; 28: 815-817.
26. Ozluk O, Kilic D, Kaygusuz S, Ceken S, Agalar C. Response to tetanus vaccination in patients with type 2 diabetes mellitus. Journal of Medicine and Medical Sciences 2010; 1: 101-105.